Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.
Morabito F, Gentile M, Monti P, Recchia AG, Menichini P, Skafi M, Atrash M, De Luca G, Bossio S, Al-Janazreh H, Galimberti S, Salah Z, Morabito L, Mujahed A, Hindiyeh M, Dono M, Fais F, Cutrona G, Neri A, Tripepi G, Fronza G, Ferrarini M. Morabito F, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2020 Aug;29(8):869-880. doi: 10.1080/13543784.2020.1783239. Epub 2020 Jun 27. Expert Opin Investig Drugs. 2020. PMID: 32551999 Free article. Review.
Lenalidomide in the treatment of chronic lymphocytic leukemia.
Gentile M, Recchia AG, Vigna E, Mazzone C, Lucia E, Gigliotti V, Bossio S, Madeo A, Morabito L, Servillo P, Franzese S, Caruso N, De Stefano L, Bisconte MG, Gentile C, Morabito F. Gentile M, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2011 Feb;20(2):273-86. doi: 10.1517/13543784.2011.546343. Epub 2011 Jan 10. Expert Opin Investig Drugs. 2011. PMID: 21214505 Review.
Promising therapies for the treatment of chronic lymphocytic leukemia.
Morabito F, Recchia AG, Vigna E, De Stefano L, Bossio S, Morabito L, Pellicanò M, Palummo A, Storino F, Caruso N, Gentile M. Morabito F, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2015 Jun;24(6):795-807. doi: 10.1517/13543784.2015.1021920. Epub 2015 Mar 1. Expert Opin Investig Drugs. 2015. PMID: 25728009 Review.
Venetoclax for the treatment of chronic lymphocytic leukemia.
Gentile M, Petrungaro A, Uccello G, Vigna E, Recchia AG, Caruso N, Bossio S, De Stefano L, Palummo A, Storino F, Martino M, Morabito F. Gentile M, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2017 Nov;26(11):1307-1316. doi: 10.1080/13543784.2017.1386173. Epub 2017 Oct 9. Expert Opin Investig Drugs. 2017. PMID: 28972395 Review.
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol.
Morabito F, Tripepi G, Vigna E, Bossio S, D'Arrigo G, Martino EA, Storino F, Recchia AG, Fronza G, Di Raimondo F, Colombo M, Fais F, Neri A, Cutrona G, Ferrarini M, Gentile M. Morabito F, et al. Among authors: bossio s. Eur J Haematol. 2021 Jun;106(6):831-835. doi: 10.1111/ejh.13614. Epub 2021 Apr 7. Eur J Haematol. 2021. PMID: 33662164 Free article. Clinical Trial.
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Recchia AG, Rossi FM, Zucchetto A, Al-Janazreh H, Martino EA, Vigna E, Tripepi G, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Jaksic O, Olivieri J, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: bossio s. Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25. Am J Hematol. 2021. PMID: 33989438 Free article. No abstract available.
lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome.
Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, Matis S, Colombo M, Galletti S, Taiana E, Recchia AG, Bossio S, Gentile M, Musolino C, Di Raimondo F, Grilli A, Bicciato S, Cortelezzi A, Tassone P, Morabito F, Ferrarini M, Neri A. Ronchetti D, et al. Among authors: bossio s. Blood Cancer J. 2016 Sep 9;6(9):e468. doi: 10.1038/bcj.2016.77. Blood Cancer J. 2016. PMID: 27611921 Free PMC article.
Janus kinase 2 inhibitors in myeloproliferative disorders.
Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F. Lucia E, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2011 Jan;20(1):41-59. doi: 10.1517/13543784.2011.538382. Epub 2010 Dec 4. Expert Opin Investig Drugs. 2011. PMID: 21128825 Review.
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
Morabito F, Mosca L, Cutrona G, Agnelli L, Tuana G, Ferracin M, Zagatti B, Lionetti M, Fabris S, Maura F, Matis S, Gentile M, Vigna E, Colombo M, Massucco C, Recchia AG, Bossio S, De Stefano L, Ilariucci F, Musolino C, Molica S, Di Raimondo F, Cortelezzi A, Tassone P, Negrini M, Monti S, Rossi D, Gaidano G, Ferrarini M, Neri A. Morabito F, et al. Among authors: bossio s. Clin Cancer Res. 2013 Nov 1;19(21):5890-900. doi: 10.1158/1078-0432.CCR-13-0622. Epub 2013 Sep 13. Clin Cancer Res. 2013. PMID: 24036852
47 results